195 related articles for article (PubMed ID: 33177346)
21. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
Lembo A; Pimentel M; Rao SS; Schoenfeld P; Cash B; Weinstock LB; Paterson C; Bortey E; Forbes WP
Gastroenterology; 2016 Dec; 151(6):1113-1121. PubMed ID: 27528177
[TBL] [Abstract][Full Text] [Related]
22. Evidence that amitriptyline may be effective in treating diarrhea-predominant irritable bowel syndrome.
Lundberg GD
Medscape J Med; 2008 Jun; 10(6):132. PubMed ID: 18679541
[No Abstract] [Full Text] [Related]
23. End points in irritable bowel syndrome.
Mangel AW; Fehnel SE
Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):293-5. PubMed ID: 21651345
[No Abstract] [Full Text] [Related]
24. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA
Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
[TBL] [Abstract][Full Text] [Related]
25. Eluxadoline approved for irritable bowel syndrome with diarrhea.
Traynor K
Am J Health Syst Pharm; 2015 Jul; 72(13):1078. PubMed ID: 26092951
[No Abstract] [Full Text] [Related]
26. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.
Shah E; Kim S; Chong K; Lembo A; Pimentel M
Am J Med; 2012 Apr; 125(4):381-93. PubMed ID: 22444104
[TBL] [Abstract][Full Text] [Related]
27. [Irritable bowel treatment].
Fassov J; Fynne L; Krarup AL
Ugeskr Laeger; 2016 Aug; 178(35):. PubMed ID: 27592867
[TBL] [Abstract][Full Text] [Related]
28. Evidence-based medicine in practice: applying intention-to-treat analysis and perprotocol analysis.
Schoenfeld PS
Am J Gastroenterol; 2005 Jan; 100(1):3-4. PubMed ID: 15654771
[No Abstract] [Full Text] [Related]
29. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials.
Qi Q; Zhang Y; Chen F; Zuo X; Li Y
BMC Gastroenterol; 2018 Jan; 18(1):5. PubMed ID: 29310568
[TBL] [Abstract][Full Text] [Related]
30. Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome.
Kasir R; Zakko S; Zakko P; Adler M; Lee A; Dhingra S; Guttermuth C
Dig Dis Sci; 2016 Mar; 61(3):846-51. PubMed ID: 26362282
[TBL] [Abstract][Full Text] [Related]
31. Ask the doctor. I have chronic diarrhea because of irritable bowel syndrome (IBS). Should I take probiotics?
Robb-Nicholson C
Harv Womens Health Watch; 2013 Mar; 20(7):2. PubMed ID: 23862208
[No Abstract] [Full Text] [Related]
32. Eluxadoline (Viberzi) for irritable bowel syndrome with diarrhea.
Med Lett Drugs Ther; 2016 Jan; 58(1485):4-5. PubMed ID: 26714241
[No Abstract] [Full Text] [Related]
33. Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome.
Whitehead WE; Duffy K; Sharpe J; Nabata T; Bruce M
Aliment Pharmacol Ther; 2017 Jan; 45(1):14-26. PubMed ID: 27910150
[TBL] [Abstract][Full Text] [Related]
34. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea.
Cash BD; Lacy BE; Schoenfeld PS; Dove LS; Covington PS
Am J Gastroenterol; 2017 Feb; 112(2):365-374. PubMed ID: 27922029
[TBL] [Abstract][Full Text] [Related]
35. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
Fukudo S; Ida M; Akiho H; Nakashima Y; Matsueda K
Clin Gastroenterol Hepatol; 2014 Jun; 12(6):953-9.e4. PubMed ID: 24315882
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Effect of Chang'an I Recipe ( I ) on Irritable Bowel Syndrome with Diarrhea: A Multicenter Randomized Double-Blind Placebo-Controlled Clinical Trial.
Tang XD; Lu B; Li ZH; Wei W; Meng LN; Li BS; Tang ZP; Gao R; Wang FY; Lu F; Bian LQ; Zhao YP; Wang P; Zhang YQ
Chin J Integr Med; 2018 Sep; 24(9):645-652. PubMed ID: 27487786
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy of fenoverine and trimebutine in the management of irritable bowel syndrome: multicenter randomized double-blind non-inferiority clinical study].
Kang SH; Jeen YT; Koo JS; Koo YS; Kim KO; Kim YS; Kim SY; Moon JS; Park JJ; Baek IH; Park SC; Lee SJ; Lee JH; Choung RS; Choi SC
Korean J Gastroenterol; 2013 Nov; 62(5):278-87. PubMed ID: 24262593
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome.
Chang FY; Lu CL; Chen CY; Luo JC
J Gastroenterol Hepatol; 2007 Dec; 22(12):2266-72. PubMed ID: 17559369
[TBL] [Abstract][Full Text] [Related]
39. Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea.
Fant RV; Henningfield JE; Cash BD; Dove LS; Covington PS
Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1021-1029.e6. PubMed ID: 28167156
[TBL] [Abstract][Full Text] [Related]
40. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.
Brenner DM; Sayuk GS
Adv Ther; 2020 Jan; 37(1):83-96. PubMed ID: 31707713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
